Theravance Study Results Confirm in vitro Potency of VIBATIV(R) (telavancin) and Efficacy in Patients With Complicated Skin and Skin Structure Infections Including MRSA

[Marketwired] – Theravance, Inc. announced today new data from multiple studies of VIBATIV® . These study results, which offer new insight into the product’s in vitro potency, efficacy and safety, will be the focus of … more

View todays social media effects on THRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Theravance is hiring next, click here to view